Current Approaches to the Treatment of Pediatric Crohn’s Disease: A Scientific Review
https://doi.org/10.15690/pf.v23i2.3030
Abstract
This review presents the main approaches to the treatment of children suffering from Crohn’s disease (CD). Special attention is paid to conservative methods, which primarily maintain remission in patients with uncomplicated forms of the disease. The cornerstone of CD treatment includes lifestyle modifications, dietary therapy, and the elimination of factors that trigger exacerbations. Pharmacological therapy has demonstrated the greatest efficacy, comprising both time-tested drugs and modern high-tech genetically engineered biological agents. Thuswise, the combination of these technologies, which reduces the frequency of relapses and improves patients’ quality of life, is widely used in the management of moderate and uncomplicated forms of CD. However, in complicated and severe cases where conservative therapy fails to produce positive results, surgical treatment methods should be considered. Currently, the laparoscopic approach is the most appropriate, characterized by lower invasiveness and a shorter recovery period. It should also be noted that disease recurrence occurs much less frequently compared to open surgical techniques. The choice of the correct therapeutic strategy remains a decisive factor in the management of pediatric patients with CD, as inappropriate tactics can lead to relapses and complications that could otherwise be avoided.
Keywords
Crohn’s disease,
genetically engineered biological therapy,
children,
diet therapy,
drug treatment,
surgical treatment
Supporting agencies: Not specified.
About the Authors
Anastasia A. Trondina
Chita State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
MD
Chita
Disclosure of interest:
Not declared.
Vladimir A. Shcherbak
Chita State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD, Professor
39A, Gorky Str., Chita, 672000
+7 (302) 235-43-24
Disclosure of interest:
Not declared.
References
1. Spasova TE. Experience of Treating Crohn’s Disease Using Genetically Engineered Biological Agents. Bulletin of Buryat State University. Medicine and Pharmacy. 2024;(1):47–52. (In Russ). doi: https://doi.org/10.18101/2306-1995-2024-1-47-52
2. Bogdanov АN, Gorbunova EV, Goryachev DV, Petraneva EV. Current Approaches to Planning and Conducting Clinical Trials of Medicinal Products for the Treatment of Crohn’s Disease. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020;10(2):111–120. (In Russ). doi: https://doi.org/10.30895/1991-2919-2020-10-2-111-120
3. Grover Z, Alex G. Management of inflammatory bowel disease in children: It is time for an individualised approach. J Paediatr Child Health. 2020;56(11):1677–1684. doi: https://doi.org/10.1111/jpc.14652
4. Zenkova KI, Skvortsova VA, Potapov AS, et al. Diet therapy in the complex treatment of children with Crohn’s disease. Rossiyskiy Pediatricheskiy Zhurnal = Russian Pediatric Journal. 2025;28(1):33–40. (In Russ). doi: https://doi.org/10.46563/10.46563/1560-9561-2025-28-1-33-40
5. Deas J, Shah ND, Konijeti GG, et al. Dietary therapies for adult and pediatric inflammatory bowel disease. Nutr Clin Pract. 2024;39(3):530–545. doi: https://doi.org/10.1002/ncp.11146
6. Gulunov ZKh, Sousova YaV, Korbesova NG. Therapeutic nutrition for Crohn’s disease. Experimental and Clinical Gastroenterology. 2025;(2):194–206. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-234-2-194-206
7. Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2021;68(6):1171–1190. doi: https://doi.org/10.1016/j.pcl.2021.07.011
8. Jasser-Nitsche H, Bechtold-Dalla Pozza S, et al. Comorbidity of inflammatory bowel disease in children and adolescents with type 1 diabetes. Acta Paediatr. 2021;110(4):1353–1358. doi: https://doi.org/10.1111/apa.15643
9. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. J Crohns Colitis. 2020;14(2):155–168. doi: https://doi.org/10.1093/eccojcc/jjz187
10. Sigall Boneh R, Westoby C, Oseran I, et al. The Crohn’s Disease Exclusion Diet: A Comprehensive Review of Evidence, Implementation Strategies, Practical Guidance, and Future Directions. Inflamm Bowel Dis. 2024;30(10):1888–1902. doi: https://doi.org/10.1093/ibd/izad255
11. Yamamoto T, Nakahigashi M, Shimoyama T, Umegae S. Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn’s disease? A case-matched study. Colorectal Dis. 2020;22(5):554–561. doi: https://doi.org/10.1111/codi.14922
12. Dalzell AM, Ba’Ath ME. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries. Paediatr Int Child Health. 2019;39(1):48–58. doi: https://doi.org/10.1080/20469047.2019.1575056
13. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1– s106. doi: https://doi.org/10.1136/gutjnl-2019-318484
14. Shcherbakova OV, Razumovskiy AYu, Shumilov PV, Ionov AL. The choice of the optimal strategy for treatment of children with Crohn’s disease and Crohn-like immunodeficiencies with perianal lesions. Voprosy detskoi dietologii = Pediatric Nutrition. 2019;17(1):7–16. (In Russ). doi: https://doi.org/10.20953/1727-5784-2019-1-7-16
15. Bikbavova GR, Akhmedov VA, Tretyakova TV, Pirozhkova AM. Management of patients with Crohn’s disease — from history to modern approaches. Medical alphabet. 2024;(26):7–14. (In Russ). doi: https://doi.org/10.33667/2078-5631-2024-26-7-14
16. Turner ST, Focht G, Orlanski-Meyer E, et al. Fatigue in pediatric inflammatory bowel diseases: A systematic review and a single center experience. J Pediatr Gastroenterol Nutr. 2024;78(2):241–251. doi: https://doi.org/10.1002/jpn3.12039
17. Rubalcava NS, Gadepalli SK. Inflammatory Bowel Disease in Children and Adolescents. Adv Pediatr. 2021;68(12):121–142. doi: https://doi.org/10.1016/j.yapd.2021.05.005
18. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi: https://doi.org/10.1093/ecco-jcc/jjz180
19. Tarashchuk AN, Zharova ME, Ivannikov IO. Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report. Russian Journal of EvidenceBased Gastroenterology. 2024;13(2):90–96. (In Russ). doi: https://doi.org/10.17116/docgastro20241302190
20. Arakelyan AL, Surkov AN, Bessonov EE, et al. Ulcerative Colitis and Crohn’s Disease in Childhood: Topical Issues and Solutions. Voprosy sovremennoi pediatrii — Current Pediatrics. 2025;24(3):146–156. (In Russ). doi: https://doi.org/10.15690/vsp.v24i3.2918
21. Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71-72:1–12. doi: https://doi.org/10.1016/j.cytogfr.2023.07.001
22. Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an openlabel multicentre randomised controlled trial. Gut. 2022;71(1):34– 42. doi: https://doi.org/10.1136/gutjnl-2020-322339
23. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–122. doi: https://doi.org/10.25122/jml-2018-0075
24. Tanida S, Mizoshita T, Ozeki K, et al. The first case of biological therapy discontinuation after a complete remission induced by maintenance therapy with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7(2):118–121. doi: https://doi.org/10.14740/jocmr1991w
25. Zhilin IV, Chashkova EYu, Zhilina АА, Gorbunov VV. The significance of gene polymorphism of some pro- and antiinflammatory cytokines in patients with severe ulcerative colitis. Transbaikalian Medical Bulletin. 2024;(2):2–10. (In Russ). doi: https://doi.org/10.52485/19986173_2024_2_1
26. Khavkin AI, Nalyotov AV, Marchenko NA. Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(6):7–15. (In Russ). doi: https://doi.org/10.22416/1382-4376-2023-33-6-7-15
27. Jois A, Alex G. Inflammatory Bowel Disease in Children. Indian J Pediatr. 2024;91(5):490–498. doi: https://doi.org/10.1007/s12098-023-04671-0
28. Samolygo IS, Aminova AI, Eryushova TYu, et al. Unusual Onset and Course of Crohn’s Disease in Children. Experimental and Clinical Gastroenterology. 2024;(6):221–224. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-226-6-221-224
29. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113(4):481–517. doi: https://doi.org/10.1038/ajg.2018.27
30. Martins R, Carmona C, George B, et al. Management of Crohn’s disease: summary of updated NICE guidance. BMJ. 2019;367:l5940. doi: https://doi.org/10.1136/bmj.l5940
31. Danilov MA, Demidova AA, Knyazev OV, Kagramanova AV. Place of Surgery in the Complex Treatment of Crohn’s Disease. Science of the young (Eruditio Juvenium). 2024;12(4):655–663. doi: https://doi.org/10.23888/HMJ2024124655-663
32. Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol. 2019;25(21):2539–2548. doi: https://doi.org/10.3748/wjg.v25. i21.2539
33. Bekin AS, D’yakonova EY, Gusev AA, et al. Outcomes after staged surgical treatment of children with ileocecal lesions and active extensive inflammation in Crohn’s disease. Russian Journal of Pediatric Surgery. 2023;27(2):82–90. (In Russ). doi: https://doi.org/10.55308/1560-9510-2023-27-2-82-90
34. Starostin AM, Vorobei AV, Shuleiko AC. Crohn’s Disease: Options and Results of Surgical treatment, Predictors of Postoperative Complications. Surgery. Eastern Europe. 2023;12(1):37–47. (In Russ). doi: https://doi.org/10.34883/PI.2023.12.1.014
35. Ponomareva MN, Karpova DA, Patrikeeva IM, et al. Ophthalmopathy in Crohn’s disease (clinical observation). Medical science and education of Ural. 2022;23(2):150–153. (In Russ). doi: https://doi.org/10.36361/18148999_2022_23_2_150
36. Uspenskiy YuP, Sarana AM, Ivanov SV, et al. Epidemiology of ulcerative colitis and Crohn’s disease: analytical data from the first regional registry of inflammatory bowel diseases of Saint Petersburg based on the state health information system. Experimental and Clinical Gastroenterology. 2025;(2):15–24. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-234-2-15-24
37. Vuijk SA, Camman AE, de Ridder L. Considerations in Paediatric and Adolescent Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(Suppl_2):ii31–ii45. doi: https://doi.org/10.1093/eccojcc/jjae087
38. Nikitina IA, Leontyev AV, Sytkov VV, et al. Treatment of perianal manifestations of Crohn’s disease. Experimental and Clinical Gastroenterology. 2025;(2):187–193. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-234-2-187-193
39. Rusova TV, Ratmanov GA. Regular medical examination of children with ulcerative colitis and Crohn’s disease. Experimental and Clinical Gastroenterology. 2019;171(11):51–58. (In Russ). doi: https://doi.org/10.31146/1682-8658-ecg-171-11-51-58
40. Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric Inflammatory Bowel Disease. Pediatrics. 2023;151(1):e2022058037. doi: https://doi.org/10.1542/peds.2022-058037
41. Tan YH, Siew JX, Thomas B, Ng KC. Patient-reported outcome measures and value-based medicine in paediatrics: a timely review. Singapore Med J. 2023;64(5):285–293. doi: https://doi.org/10.11622/smedj.2021102
42. Arakelyan AL, Surkov AN, Baranov AA, et al. Linguistic accuracy and authenticity of the content of the Russian version of the module of gastrointestinal symptoms of the PedsQL™ questionnaire for pediatric patients. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2023;20(2):112–119. (In Russ). doi: https://doi.org/10.15690/pf.v20i2.2553
43. Felipez LM, Ali S, de Zoeten EF, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025;81(4):1100– 1117. doi: https://doi.org/10.1002/jpn3.70158
Review
For citations:
Trondina A.A., Shcherbak V.A. Current Approaches to the Treatment of Pediatric Crohn’s Disease: A Scientific Review. Pediatric pharmacology. 2026;23(2):89-95. (In Russ.) https://doi.org/10.15690/pf.v23i2.3030
Views:
192
JATS XML
Email this article 